Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.

Perfetti R, Bailey E, Wang S, Mills R, Mohanlal R, Shendelman S

Open source

DOI
10.1002/jcph.2495
Published
2024 Nov
Container
Journal of clinical pharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jcph.2495,
  title = {Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.},
  author = {Perfetti R and Bailey E and Wang S and Mills R and Mohanlal R and Shendelman S},
  year = {2024},
  journal = {Journal of clinical pharmacology},
  doi = {10.1002/jcph.2495},
  url = {https://doi.org/10.1002/jcph.2495}
}

RIS

TY  - JOUR
TI  - Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.
AU  - Perfetti R
AU  - Bailey E
AU  - Wang S
AU  - Mills R
AU  - Mohanlal R
AU  - Shendelman S
PY  - 2024
JO  - Journal of clinical pharmacology
DO  - 10.1002/jcph.2495
UR  - https://doi.org/10.1002/jcph.2495
ER  - 

APA

R, P., E, B., S, W., R, M., R, M., & S, S. (2024). Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.2495

Source records